A-E: Tracings of whole mount immunofluorescence from (A) TrkBCreER; AdvillinFlp; R26FSF-LSL-tdTomato mice (0.005mg tamoxifen at P5); (B) THCreER; Phox2B-Flp; R26FRT-LSL-tdTomato-FRT mice (0.1mg tamoxifen at P24); (C) Bmpr1bCreER; Calca-Flp; R26FSF-LSL-tdTomato mice (1–3mg tamoxifen at P21); (D) Sstr2CreER; Calca-Flp; R26FSF-LSL-tdTomato mice (0.05mg tamoxifen at P21); and (E) Adra2aCreER; Calca-Flp; R26FSF-LSL-tdTomato mice (1mg tamoxifen P21–25 and 4mg 8 weeks), all treated with low amounts of tamoxifen to achieve sparse labeling. Animals were sacrificed after P21 and at least 2 weeks after last tamoxifen dose. All scale bars are 100 μm unless otherwise specified.
F: Graph summarizing ending termination location in the colon wall for the genetically labeled subtypes.
G: Graph quantifying myenteric cell body wrappings observed with individual IGVEs by genetic subtype. Each point represents an individual ending.
H-J: Graphs quantifying total ending length (H), width (I), or branches (J). Each point represents an individual ending.
K: Diagram showing the colonic morphologies of distinct DRG afferent subtypes.